Skip to main content
PLOS One logoLink to PLOS One
. 2021 Apr 21;16(4):e0250213. doi: 10.1371/journal.pone.0250213

Comparing the effectiveness of negative-pressure barrier devices in providing air clearance to prevent aerosol transmission

Tzu-Yao Hung 1,2,3,4,, Wei-Lun Chen 1,, Yung-Cheng Su 5,6, Chih-Chieh Wu 1, Tzu-Yao Chueh 7, Hsin-Ling Chen 1,*,#, Shih-Cheng Hu 7,*,#, Tee Lin 7,*,#
Editor: Jianguo Wang8
PMCID: PMC8059829  PMID: 33882091

Abstract

Purpose

To investigate the effectiveness of aerosol clearance using an aerosol box, aerosol bag, wall suction, and a high-efficiency particulate air (HEPA) filter evacuator to prevent aerosol transmission.

Methods

The flow field was visualized using three protective device settings (an aerosol box, and an aerosol bag with and without sealed working channels) and four suction settings (no suction, wall suction, and a HEPA filter evacuator at flow rates of 415 liters per minute [LPM] and 530 LPM). All 12 subgroups were compared with a no intervention group. The primary outcome, aerosol concentration, was measured at the head, trunk, and foot of a mannequin.

Results

The mean aerosol concentration was reduced at the head (p < 0.001) but increased at the feet (p = 0.005) with an aerosol box compared with no intervention. Non-sealed aerosol bags increased exposure at the head and trunk (both, p < 0.001). Sealed aerosol bags reduced aerosol concentration at the head, trunk, and foot of the mannequin (p < 0.001). A sealed aerosol bag alone, with wall suction, or with a HEPA filter evacuator reduced the aerosol concentration at the head by 7.15%, 36.61%, and 84.70%, respectively (99.9% confidence interval [CI]: -4.51–18.81, 27.48–45.73, and 78.99–90.40); trunk by 70.95%, 73.99%, and 91.59%, respectively (99.9% CI: 59.83–82.07, 52.64–95.33, and 87.51–95.66); and feet by 69.16%, 75.57%, and 92.30%, respectively (99.9% CI: 63.18–75.15, 69.76–81.37, and 88.18–96.42), compared with an aerosol box alone.

Conclusions

As aerosols spread, an airtight container with sealed working channels is effective when combined with suction devices.

Introduction

The highest concentrations of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) are found in the saliva, sputum, and upper airway secretions [1]. Coronavirus disease (COVID-19) may spread through small droplets or aerosols [28]. Compared with droplets, aerosols spread more easily and also remain in the air for a longer period of time. Aerosols can be generated through coughing, talking, sneezing, breathing, during oxygenation using a high-flow facility, before or during the intubation process, and when managing a deteriorated airway in patients with COVID-19 [2,410]. To date, there have been no clinical experiments regarding SARS-CoV-2 aerosol transmission; however, animal models have provided direct evidence that aerosols are an important means of transmission [11].

Several guidelines have recommended the routine use of personal protective equipment (PPE) during high-risk procedures, such as tracheal intubation [6,7,12,13]. Furthermore, novel barrier equipment, such as aerosol boxes (AB) and disposable plastic aerosol bags, have been developed to reduce droplet spillage and transmission risk [1420]. AB (Taiwan box) is a pioneer public-shared barrier design for effectively preventing droplet spillage [18,21]. Another novel method involves a disposable plastic aerosol bag clipped by strings attached to the surgical lamp in the resuscitation room. This creates a negative-pressure barrier with the wall suction and can be used to reduce the risk of fomite transmission when considering the possibility of inadequate disinfection [19].

To accelerate viral concentration clearance in the air, wall suction is an easily accessible method that can be used to create negative pressure, and this may be useful in combination with protective barriers [19,22]. The high-efficiency particulate air (HEPA) filtering evacuator is another accessible device that is widely used in dermatological interventions such as cryotherapy of pathological lesions infected with human papillomavirus. Furthermore, the HEPA filtering evacuator has been used for pathogens smaller than SARS-CoV-2.

Daily human activity also leads to the production of bioaerosols: breathing (<0.8–2μm), speaking (<0.8–7μm, 16–125μm), shouting (0.5–10μm), coughing (0.62–15.9μm, 40–125μm), and sneezing (7–125μm) [9]. This study aimed to investigate three different devices (an AB and an aerosol bag with and without sealed working channels) in combination with or without suction systems for aerosol protection via flow field visualization. We also aimed to investigate the detection of aerosol exposure during tracheal intubation in order to identify the best negative-pressure barrier system for the protection of healthcare workers from aerosol-generating procedures.

Methods

Study design and setting

This in situ study was performed in a negative-pressure resuscitation room, with 12 air changes per hour, located at Taipei City Hospital, Zhong-Xing branch, a metropolitan teaching and designated COVID-19 treatment hospital in Taiwan.

The background flow of the resuscitation room runs from the top of the space to four vents at the bottom of each corner and occurs in a downward direction. A simulated mannequin (Laerdal® Airway Management Trainer, Laerdal, New York, USA) was positioned in an inclined head-up 30° position, and the trachea was connected to a three-dimensional printed ventilator (Massachusetts Institute of Technology Emergency Ventilator, Massachusetts, USA [23]) and a smoke particle generator (MPL-I003, Tong-Da, Tainan, Taiwan) to create visible smoke (atomized glycerol) from the mouth of the mannequin (Fig 1A). The breathing cycle was set to a fixed rate of 25 times per minute and created a minute ventilation of approximately 10 liters per minute (LPM) to simulate a tachypneic patient. Large-area particle image velocimetry (PIV) was applied to analyze the dynamic flow field of the air during the breathing cycle. A high-sensitivity camera (ORCA-Flash 4.0 v2 digital CMOS camera, Hamamatsu Co., Hamamatsu, Japan) was set in a vertical direction 2 m away from the head of the mannequin to record the light source scattered by the tracer gas of glycerol after being irradiated by the green laser.

Fig 1.

Fig 1

Two novel protective devices: A. Experimental setting. The ventilator was connected to a smoke generator and air supplement system; then, the ventilator was set to 25 breathing cycles per minute (10 L/min) and attached to the mannequin. A green laser was ejected from the foot and trunk of the mannequin to demonstrate the aerosol in two vertical dimensions. B. Aerosol concentration experimental setting. The ventilator was connected with the smoke generator and the mannequin, and the particles were pumped out during the breathing cycle, simulating aerosols. The upstream detector of the aerosol photometer was placed by the mouth of the mannequin, while the downstream detector was placed in the three spots (head, trunk, and foot of the mannequin). C. Aerosol box (side view), a shield-like device, covers the front, top, and two lateral sides; the rear side is left open for equipment transfer. There were two working channels in the front of the box, and two at each lateral side of the box for airway management. D. The wall suction was attached at the chin of the mannequin using an elastic adhesive tape. E. The high-efficiency particulate air (HEPA) evacuator was equipped with a metal stand that can clip and fix the suction tube upright just above the chin of the mannequin. F. Disposable transparent plastic bag (aerosol bag).

To investigate the concentration of the contaminated aerosol, the glycerol tracer gas was then replaced with polyalphaolefin (PAO) (with a diameter of 0.5–0.7 μm). Three spots around the mannequin (head, trunk, and foot) were assessed with a light-scattering photometer with a sampling rate of 28.3 LPM in 180 s intervals (Fig 1B and 1D) to evaluate the aerosol exposure of healthcare workers. Between each setting, detection only started after the concentration of PAO dropped to less than 0.005% (background level).

Interventions

Two novel protective devices were investigated, an AB and a plastic disposable aerosol bag (PDAB) with and without two sealed working channels (three protective device settings). The AB was a box-like shield with dimensions of 50 cm × 35 cm × 55 cm with no rear plane; two working channels on the front and one working channel was attached on each side of the lateral plane for airway management (Fig 1C and 1D). A PDAB (60 cm × 70 cm) was attached to the surgical light in the resuscitation room and was sufficient to cover the head, shoulder, and the upper chest of the mannequin (Fig 1E).

The following two suction devices were evaluated during the study: a wall suction (3-Stages Analogue Vacuum Regulator, maximum flow rate 36 LPM, Pacific Hospital Supply Co., Taipei, Taiwan) and an evacuator with a HEPA filter (Surgifresh Mini TURBO Smoke Evacuators, with a minimum flow rate of 415 LPM, and a maximum of 530 LPM, Dynamic Medical Technologies, Taipei, Taiwan). The suction devices were placed on the chin of the mannequin.

Two protective devices with three settings (AB, non-sealed working channels PDAB, sealed working channels PDAB) and two suction devices with four settings (no suction device, wall suction at a flow rate of 36 LPM, and HEPA filter evacuator at flow rates of 415 LPM and 530 LPM) created 12 (3 × 4) possible conditions, all of which were compared with the no intervention condition (total 13 subgroups).

Measurements

The flow field visualization was recorded by a high-sensitivity camera in both sagittal and coronal views. The background flow field was recorded first. A total of 13 different settings were recorded: no intervention, AB, AB with wall suction at a flow rate of 36 LPM, and AB with HEPA filter evacuator (HE) at a flow rate of 415 LPM and 530 LPM; DPAB without sealed working channels (DPAB-NS), DPAB-NS with wall suction, and DPAB-NS with HE at 415 LPM and 530 LPM; DPAB with seal (DPAB-S) and DPAB-S with wall suction; and DPAB-S with HE at 415 LPM and 530 LPM. The primary outcome was PAO concentration at the head, trunk, and foot of the mannequin at an interval of 180 s among 13 subgroups.

Statistical analysis

Student t-tests were used to evaluate the percentage differences between each protective equipment setting. SAS statistical package version 9.4 (SAS Institute, Inc., North Carolina, USA) and STATA version 15.1 (StataCorp, Texas, USA) were used for all data analysis.

Two-tailed p-values <0.001 were considered to be statistically significant.

The sample size calculation for this experiment was based on an initial pilot experiment showing that an average concentration of 600 ppm was detected at the head side when no protective equipment was used. To detect a mean percentage difference of 20% from the baseline level, a two-sided significance level of 0.1%, and power of 80%, an estimated 394 participants were needed per device tested. We have accounted for multiple testing issues using Bonferroni correction method. There was a control group; further, 12 groups with 3 different detecting positions for estimation were also present, bringing the total to 36 comparisons. We adjusted the p-value of significance to 0.001 because of the large number of pairwise comparisons. As this was a simulated mannequin study and involved no human participants, ethical approval was not required.

Results

Particle visualization images from the sagittal and coronal views showed that aerosol particles can escape from the working channels of AB and DPAB-NS. The aerosols moved along the top of the AB to the foot of the mannequin (Fig 2A). However, DPAB-S had a better ability to confine the aerosol particles without visible aerosol escape.

Fig 2. Particle visualization images in both the sagittal and coronal views.

Fig 2

A. Sagittal view of the aerosol box containing aerosols; aerosol movement is visualized with green vector arrows in the visualized flow field. The white arrows indicate the aerosols moving to the foot of the mannequin. The white arrowheads indicate leakage of aerosols from the front non-sealed working channels. B. Coronal view of the visualized flow field. The white arrowheads indicate aerosol escape from the side non-sealed working channels.

With regard to suction devices, wall suction decreased the escape of the aerosol particles when used in combination with AB and DPAB-NS. However, aerosol escape was still observed in the coronal view of AB. The minimum (415 LPM) or maximum (530 LPM) HE flow rate decreased the dispersion of the aerosols, and there was no visualized escape. DPAB-S showed no visualized aerosol escape with and without all suction systems.

Compared to baseline concentrations without intervention, AB decreased the aerosol exposure at the head of the mannequin, but this was increased at the foot of the mannequin (p = 0.05). DPAB-NS decreased exposure at the foot of the mannequin; however, exposure at the head and trunk of the mannequin markedly increased. DPAB-S had lowest exposure among the barriers at all detection sites of all the cases without suction devices (Table 1).

Table 1. Aerosol concentration of the control group and 12 different subgroup settings at the head, trunk, and foot of the mannequin.

N Group Suction Device (LPM) Mean (ppm) p-value 99.9% CI
499 No intervention 662.03 565.83 ~ 758.24
H 495 Aerosol Box 483.80 <0.001 450.36 ~ 517.24
490 Aerosol Box + Wall suction 36 277.36 <0.001 256.63 ~ 298.08
473 Aerosol Box + HEPA evacuator 415 47.27 <0.001 44.74 ~ 49.80
E 487 Aerosol Box + HEPA evacuator 530 26.07 <0.001 24.88 ~ 27.27
498 Non-sealed aerosol bag 1214.25 <0.001 92.36 ~ 1500.14
510 Non-sealed aerosol bag + Wall suction 36 266.40 <0.001 224.00 ~ 308.80
A 471 Non-sealed aerosol bag + HEPA evacuator 415 47.27 <0.001 44.73 ~ 49.80
488 Non-sealed aerosol bag + HEPA evacuator 530 26.01 <0.001 24.82 ~ 27.21
489 Sealed Aerosol bag 449.20 <0.001 403.41 ~ 494.99
D 488 Sealed Aerosol bag + Wall suction 36 175.83 <0.001 161.22 ~ 190.44
480 Sealed Aerosol bag + HEPA evacuator 415 7.23 <0.001 6.23 ~ 8.23
486 Sealed Aerosol bag + HEPA evacuator 530 5.19 <0.001 4.57 ~ 5.82
T 493 No intervention 345.83 321.76 ~ 369.89
508 Aerosol Box 410.21 <0.001 366.91 ~ 453.51
R 494 Aerosol Box + Wall suction 36 241.08 <0.001 190.26 ~ 291.90
478 Aerosol Box + HEPA evacuator 415 38.91 <0.001 37.39 ~ 40.42
477 Aerosol Box + HEPA evacuator 530 23.56 <0.001 22.43 ~ 24.68
U 504 Non-sealed aerosol bag 7705.68 <0.001 5651.59 ~ 9759.76
499 Non-sealed aerosol bag + Wall suction 36 855.73 <0.001 513.26 ~ 1198.20
474 Non-sealed aerosol bag + HEPA evacuator 415 38.79 <0.001 37.34 ~ 40.23
N 475 Non-sealed aerosol bag + HEPA evacuator 530 23.53 <0.001 22.41 ~ 24.66
484 Sealed Aerosol bag 119.17 <0.001 107.69 ~ 130.66
483 Sealed Aerosol bag + Wall suction 36 62.71 <0.001 57.91 ~ 67.52
K 494 Sealed Aerosol bag + HEPA evacuator 415 3.27 <0.001 2.73 ~ 3.81
495 Sealed Aerosol bag + HEPA evacuator 530 2.83 <0.001 2.16 ~ 3.51
494 No intervention 693.07 642.78 ~ 743.36
F 504 Aerosol Box 748.31 0.005 707.93 ~ 788.69
499 Aerosol Box + Wall suction 36 450.01 <0.001 425.50 ~ 474.52
472 Aerosol Box + HEPA evacuator 415 26.78 <0.001 25.71 ~ 27.85
O 487 Aerosol Box + HEPA evacuator 530 28.17 <0.001 27.10 ~ 29.23
500 Non-sealed aerosol bag 462.41 <0.001 391.65 ~ 533.18
506 Non-sealed aerosol bag + Wall suction 36 144.23 <0.001 130.72 ~ 157.73
O 470 Non-sealed aerosol bag + HEPA evacuator 415 26.74 <0.001 25.67 ~ 27.81
477 Non-sealed aerosol bag + HEPA evacuator 530 28.24 <0.001 27.16 ~ 29.31
487 Sealed Aerosol bag 230.74 <0.001 212.20 ~ 249.29
T 486 Sealed Aerosol bag + Wall suction 36 109.95 <0.001 101.53 ~ 118.37
495 Sealed Aerosol bag + HEPA evacuator 415 2.06 <0.001 1.70 ~ 2.42
495 Sealed Aerosol bag + HEPA evacuator 530 1.77 <0.001 1.45 ~ 2.09

HEPA, high-efficiency particulate air; LPM, liters per minute.

In combination with wall suction at a flow rate of 36 LPM, aerosol exposure decreased significantly (p<0.001) with AB, DPAB-NS, and DPAB-S. However, AB still showed the highest exposure of all the barriers at the foot of the mannequin; the highest aerosol concentration at the trunk of the mannequin was found with DPAB-NS. Of all the barrier devices, DPAB-S showed the lowest aerosol concentration at all three detection sites (Table 1).

In combination with HE at a flow rate of 415 and 530 LPM, aerosol exposure was very low with all three barrier devices. Overall, the DPAB-S subgroup showed the lowest concentration compared with other subgroups (Table 1).

With suction, AB was found to be more protective for workers at the head and the trunk of the mannequin but worse for those at the foot of the mannequin, compared with the protective effect of DPAB-NS (Table 1). However, without the suction system, DPAB-S was the best barrier device at all three detection sites (all, p < 0.001).

Comparing the three devices (AB, DPAB-NS, and DPAB-S) in combination with the three suction settings (wall suction at 36 LPM, HE at 415 LPM, and HE at 530 LPM), DPAB-S showed a better protective effect from the aerosols than AB (Table 2) at all three detection sites (head, trunk, and foot) of the mannequin (p < 0.001). For non-sealed barriers, AB with wall suction was protective at the trunk of the mannequin but not at the foot of the mannequin, as compared to DPAB-NS (p < 0.001). With HE, there were no differences between DPAB-NS and AB at any of the three detection sites (Table 2).

Table 2. Non-sealed and sealed aerosol bags versus aerosol boxes in combination with or without suction devices.

Settings Suction Device Mean Percentage Difference(%)* 99.9% Confidence Interval(%) p-value
Aerosol Box vs. Non-sealed Aerosol Bag None -150.98 -210.47 to -91.49 <0.001
H Aerosol Box vs. Sealed Aerosol Bag None 7.15 -4.51~ 18.81 0.044
E Aerosol Box vs. Non-sealed Aerosol Bag Wall Suction 3.95 -13.23~ 21.13 0.424
A Aerosol Box vs. Sealed Aerosol Bag Wall Suction 36.61 27.48~ 45.73 <0.001
D Aerosol Box vs. Non-sealed Aerosol Bag HEPA Evacuator (415 LPM) 0.01 -7.55~ 7.57 0.996
Aerosol Box vs. Sealed Aerosol Bag HEPA Evacuator (415 LPM) 84.70 78.99~ 90.40 <0.001
Aerosol Box vs. Non-sealed Aerosol Bag None -1778.48 -2275.88 to -1281.08 <0.001
T Aerosol Box vs. Sealed Aerosol Bag None 70.95 59.83~ 82.07 <0.001
R Aerosol Box vs. Non-sealed Aerosol Bag Wall Suction -254.96 -398.84 to -111.08 <0.001
U Aerosol Box vs. Sealed Aerosol Bag Wall Suction 73.99 52.64~ 95.33 <0.001
N Aerosol Box vs. Non-sealed Aerosol Bag HEPA Evacuator (415 LPM) 0.30 -5.07 to 5.67 0.854
K Aerosol Box vs. Sealed Aerosol Bag HEPA Evacuator (415 LPM) 91.59 87.51~ 95.66 <0.001
Aerosol Box vs. Non-sealed Aerosol Bag None 38.21 27.37~ 49.04 <0.001
F Aerosol Box vs. Sealed Aerosol Bag None 69.16 63.18~ 75.15 <0.001
O Aerosol Box vs. Non-sealed Aerosol Bag Wall Suction 67.95 61.77~ 74.13 <0.001
O Aerosol Box vs. Sealed Aerosol Bag Wall Suction 75.57 69.76~ 81.37 <0.001
T Aerosol Box vs. Non-sealed Aerosol Bag HEPA Evacuator (415 LPM) 0.15 -5.47 to 5.78 0.928
Aerosol Box vs. Sealed Aerosol Bag HEPA Evacuator (415 LPM) 92.30 88.18~ 96.42 <0.001

HEPA, high-efficiency particulate air; LPM, liters per minute.

Discussion

The COVID-19 pandemic has driven clinicians to develop devices that protect healthcare workers from nosocomial infections during tracheal intubation [1421]. The Taiwan box is a pioneering public-shared design [21]. Canelli et al. found that such an AB can prevent droplet spillage and splashes while a patient is coughing [18]. We also fabricated a device with a single-use plastic bag to create a negative-pressure barrier with the wall suction (published on April 1st, 2020). Any other such sufficiently large transparent plastic bag can be used for this negative barrier system (Figs 1E and 3A–3D) [19]. However, the effectiveness of these protective devices is controversial; Begley et al. found that the AB may increase intubation time and decrease the first-pass success [15].

Fig 3.

Fig 3

A-D. The drill performed with a disposable plastic aerosol bag with sealed working channels (DPAB-S). White arrows indicate the elastic adhesive bandages used to seal the working channels; white arrowheads indicate the suction tube located on the chin of the mannequin. E. When managing patients with a thick beard, a plastic wrap can help fix the suction tube to the patient’s chin.

Flow visualization using the laser PIV technique [24,25], found that the aerosol flowed upward and then followed the top curve of AB to the foot of the mannequin, which could be a health hazard if the health workers at the foot wore insufficient PPE (Fig 2A, S1 Video). Furthermore, the flow can escape significantly from the non-sealed working channels with time, thus being even more dangerous (Fig 4A–4F). When the plastic aerosol bag was sealed with a working channel to form an airtight container, the aerosols were confined better, without significant leakage. Sealing of the working channels can improve aerosol entrapment efficiency. When using a wall suction at 36 LPM, the clearance of aerosols was insufficient; clearance improved with time if this was combined with the AB (Fig 4D–4F blue line) and DPAB-NS (Fig 4D–4F pink line). With HE at flow rates of 415 and 530 LPM, aerosol clearance was fast, without visible aerosol flow escaping from the rear end and working channels of AB; the plastic aerosol bag also showed similar results.

Fig 4. The aerosol concentration of the 13 different subgroups during a 180 s interval (vertical axis: Concentration, 0–0.2%; horizontal axis: Time, 0–180 s).

Fig 4

Black line: No intervention; blue line: aerosol box; pink line: Non-sealed aerosol bag; green line: Sealed aerosol bag. A, B, and C (upper row) are head, trunk, and foot, with no suction. D, E, and F (middle row) are head, trunk, and foot, with wall suction. G, H, and I (bottom row) are the head, trunk, and foot, with high-efficiency particulate air (HEPA) filter evacuator at 415 liters per minute (LPM) and 530 LPM. Aerosol box (blue line) showed increasing aerosol concentration at the foot of the mannequin with time. Non-sealed aerosol bag (pink line) was hazardous for the healthcare workers at the head and trunk. A sealed aerosol bag (green line) showed better protective effect. With the HEPA filter evacuator, the aerosol concentrations were stable and low constantly (bottom row).

Simpson et al. investigated the function of four protective devices using aerosols (AB, sealed box, and vertical and horizontal drapes) and found that AB and horizontal and vertical plastic drapes were of no use and might increase the aerosol contamination in the intubator [22]. To further investigate aerosol exposure, we chose three sites to record aerosol concentration: the intubator (head), first assistant (trunk), and second assistant (foot). We found that the use of AB can lead to reduction in intubator exposure. However, the aerosol concentration at the foot of the mannequin was even higher than that at the head of the mannequin (Fig 2A, white arrows, Fig 4A–4C, blue line). With DPAB-NS, a significant amount of aerosol escaped from the working channels near the head and trunk, thus posing a hazard to both the intubator and first assistant (Fig 4A–4E pink line, Table 1). Wall suction with AB significantly reduced aerosols at the head of the mannequin; however, aerosol concentration was markedly higher on the foot side, compared to no intervention; DPAB-NS with wall suction markedly increased the head and trunk-side exposure, only reducing the exposure at the foot, compared to the no intervention group (Table 1). HE showed sufficient ability for aerosol clearance without leakage with AB and DPAB at all times (Fig 4G–4I).

The working channels of AB and DPAB enable intubation to be performed; however, aerosols were found to escape from these channels, as assessed through flow field visualization and quantification of aerosol concentration (Fig 2, white arrowhead; Fig 4A–4F blue and pink line). Thus, sealing of these channels is crucial for preventing the spread of aerosols and for the protection of healthcare workers; this should, therefore, be recommended. DPAB-S significantly reduced the aerosols at all areas where measurement was performed, with and without suction systems (Table 1). Without the suction system, DPAB-S still reduced aerosol concentrations at the head, trunk, and foot of the mannequin, and this was done to a greater degree than that of AB (Table 2). With the wall suction at a flow rate of 36 LPM at the mouth of the mannequin, DPAB-S reduced aerosol concentrations at the head, trunk, and foot of the mannequin to a greater degree than that of AB. If used with HE at a flow rate of 415 and 530 LPM, DPAB-S reduced the aerosols at the head, trunk, and foot of the mannequin, and to a greater degree than that of AB (Table 2). However, a team-based practice or a drill should be performed to become familiar with the process before using these barriers with sealed working channels during negative-pressure barrier airway management. During our drills, we attached elastic adhesive bandages to seal the working channels with the intubator’s forearms (Fig 3A–3D). The flexible nature of DPAB-S allowed the intubator to manage the airway. The assistants need to seal the working channels and activate the suction devices. However, exaggerated movement of the intubator needs to be avoided to minimize the aerosol dispersion. As shown in Fig 3E, a plastic wrap should be applied to fix the wall suction tube to the patient’s chin if managing a patient with a thick beard. A stepwise airway management plan should be practiced.

Wall suction is readily available in different units of hospitals and in ambulances and is easier to use in combination with PPE and a barrier to create a negative-pressure environment. Simpson et al. found that a sealed AB along with wall suction was the only effective setting to reduce aerosol concentration compared to AB without seal and the use of vertical and horizontal drapes [22]. In our study, the wall suction located on the chin of the mannequin (Fig 1D) reduced the concentration of aerosols to some extent; the aerosols were also observed to slightly accumulate and escape from the protective devices over time if the working channels were not sealed (Fig 4D–4F). However, the trend of aerosol concentration was flat and reduced compared to that in the no-suction system subgroups (Fig 4A–4C). In this current study, HE provided sufficient clearance ability, prevented aerosol escape, and increased the safety of protective devices (Table 1). AB is a firm shield that cannot confine aerosols in the same way as DPAB or drapes. However, it is easier to form a closed system and confine the aerosols if the channels are sealed (Tables 1 and 2, Fig 3). The entrapment ability of the protective device and clearing efficiency of the suction system create the best combination of negative-pressure barriers for use during aerosol-generating procedures.

This study has some limitations. First, this was a simulation study and may not represent actual clinical conditions. Minute ventilation was simulated at a fixed rate of 10 LPM, which may not be comparable with human lung physiology. A patient with respiratory failure may present with larger minute ventilation that may be as high as 40–120 LPM. However, the result was still significant, even with a relatively small minute ventilation. Furthermore, intubating patients with COVID-19 in respiratory failure while wearing PPE and using a negative-pressure barrier system requires practice. If untrained, 100–180 s may not be sufficient for the intubation process. The study was also conducted in a negative-pressure room with 12 air changes per hour, and this only meets the minimum requirement of the American Society of Anesthesiologists guidelines for caring for COVID-19 patients. The aerosol concentration may be reduced in a room that has higher air changes per hour. Finally, before applying sealed working channel barriers, team-based practice sessions should be performed to ensure that the fully PPE-equipped intubator and the assistants can cooperate well while working to avoid delays in airway management.

Conclusions

To facilitate the elimination of the aerosols, wall suction can, to some extent, provide clearing ability; however, the aerosols will still increase within 180 s. HE, at a flow rate of ≥415 LPM, forms a safe negative protective system with both AB and DPAB, and this will be suitable for healthcare workers performing aerosol-generating procedures, especially during pandemics, such as the current COVID-19 outbreak. A negative-pressure barrier consisting of an airtight container and suction devices with sufficient aerosol elimination is effective for aerosol protection.

Supporting information

S1 Video. The video demonstrates the aerosol movement to the foot and escape from the working channels of the aerosol box without suction systems.

(MP4)

Data Availability

All relevant data are within the paper and its Supporting Information files.

Funding Statement

This study was funded by the department of health, Taipei City Government, Taiwan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020;20(5): 565–574. 10.1016/S1473-3099(20)30196-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Gralton J, Tovey E, McLaws M-L, Rawlinson WD. The role of particle size in aerosolised pathogen transmission: a review. J Infect. 2011;62(1): 1–13. 10.1016/j.jinf.2010.11.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Pasnick S, Carlos WG, Dela Crus CS, Gross JE, Garrison G, Jamil S. SARS-CoV-2 transmission and the risk of aerosol-generating procedures. Am J Respir Crit Care Med. 2020;202 (4): P13–P14. 10.1164/rccm.2024P13 [DOI] [PubMed] [Google Scholar]
  • 4.Tran K, Cimon K, Severn M, Pessoa-Silva CI, Conly J. Aerosol-generating procedures and risk of transmission of acute respiratory infections: a systematic review. CADTH Technol Overv. 2013;3(1): e3201. [PMC free article] [PubMed] [Google Scholar]
  • 5.Anderson EL, Turnham P, Griffin JR, Clarke CC. Consideration of the aerosol transmission for COVID-19 and public health. Risk Anal. 2020;40(5): 902–907. 10.1111/risa.13500 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Banik RK, Ulrich AK. Evidence of short-range aerosol transmission of SARS-CoV-2 and call for universal airborne precautions for anesthesiologists during the COVID-19 pandemic. Anesth Analg. 2020;131(2): e102–e104. 10.1213/ANE.0000000000004933 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Howard BE. High-risk aerosol-generating procedures in COVID-19: Respiratory protective qquipment considerations. Otolaryngol Head Neck Surg. 2020;163(1): 98–103. 10.1177/0194599820927335 [DOI] [PubMed] [Google Scholar]
  • 8.Kohanski MA, Palmer JN, Cohen NA. Aerosol or droplet: critical definitions in the COVID-19 era. Int Forum Allergy Rhinol. 2020;10(8): 968–969. 10.1002/alr.22591 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Tellier R, Li Y, Cowling BJ, Tang JW-T. Recognition of aerosol transmission of infectious agents: a commentary. BMC Infect Dis. 2019;19(1): 101. 10.1186/s12879-019-3707-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Mintz Y, Arezzo A, Boni L, Baldari L, Cassinotti E, Brodie R, et al. The risk of COVID-19 transmission by laparoscopic smoke may be lower than for laparotomy: a narrative review. Surg Endosc. 2020. Aug;34(8):3298–3305. 10.1007/s00464-020-07652-y Epub 2020 May 26. ; PMCID: PMC7250491. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Bao L, Gao H, Deng W, Lv Q, Yu H, Liu M, et al. Transmission of SARS-CoV-2 via close contact and respiratory droplets among hACE2 mice. J Infect Dis. 2020;jiaa281 10.1093/infdis/jiaa281 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Brewster DJ, Chrimes N, Do TB, Fraser K, Groombridge CJ, Higgs A, et al. Consensus statement: Safe Airway Society principles of airway management and tracheal intubation specific to the COVID-19 adult patient group. Med J Aust. 2020;212(10): 472–481. 10.5694/mja2.50598 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Szarpak L, Drozd A, Smereka J. Airway management and ventilation principles in COVID-19 patients. J Clin Anesth. 2020;65: 109877. 10.1016/j.jclinane.2020.109877 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Rahmoune FC, Ben Yahia MM, Haijei R, Pic S, Chatti K. Protective device during airway management in patients with coronavirus disease 2019 (COVID-19). Anesthesiology, 2020;133(2): 473–475. 10.1097/ALN.0000000000003369 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Begley JL, Lavery KE, Nickson CP, Brewster DJ. The aerosol box for intubation in coronavirus disease 2019 patients: an in-situ simulation crossover study. Anaesthesia. 2020;75(8): 1014–1021. 10.1111/anae.15115 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Bianco F, Incollingo P, Grossi U, Gallo G. Preventing transmission among operating room staff during COVID-19 pandemic: the role of the Aerosol Box and other personal protective equipment. Updates Surg. 2020;72(3): 907–910. 10.1007/s13304-020-00818-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Brown H, Preston D, Bhoja R. Thinking Outside the Box.: A low-cost and pragmatic alternative to aerosol boxes for endotracheal intubation of COVID-19 patients. Anesthesiology. 2020;133(3): 683–684. 10.1097/ALN.0000000000003422 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Canelli R, Connor CW, Gonzales M, Nozari A, Ortega R. Barrier enclosure during endotracheal intubation. N Engl J Med. 2020;382(20): 1957–1958. 10.1056/NEJMc2007589 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Lin LW, Hung TY. Swivel-HEPA-ETT (SHE) bougie and HEPA-ETT (HE) methods for safe intubation while managing patients with COVID-19. Emerg Med. 2020;37(5): 256–257. 10.1136/emermed-2020-209625 [DOI] [PubMed] [Google Scholar]
  • 20.Mintz Y, Arezzo A, Boni L, Chand M, Brodie R, Fingerhut A; and the Technology Committee of the European Association for Endoscopic Surgery. A Low-cost, Safe, and Effective Method for Smoke Evacuation in Laparoscopic Surgery for Suspected Coronavirus Patients. Ann Surg. 2020. Jul;272(1):e7–e8. 10.1097/SLA.0000000000003965 ; PMCID: PMC7188054. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Everington K. Taiwanese doctor invents device to protect US doctors against coronavirus. 2020. Available from: https://www.taiwannews.com.tw/en/news/3902435. [Accessed on Jan. 5th 2021]. [Google Scholar]
  • 22.Simpson JP, Wong DN, Verko L, Carter R, Dzidowski M, Chan PY. Measurement of airborne particle exposure during simulated tracheal intubation using various proposed aerosol containment devices during the COVID-19 pandemic. Anaesthesia. 2020;75(12): 1587–1595. 10.1111/anae.15188 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.MIT. MIT Emergency Ventilator. 2020; Available from: https://emergency-vent.mit.edu/ [Accessed on Jan. 5th 2021]. 10.1126/scitranslmed.abb9401 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Lin T, Zargar O, Lin K-Y, et al. An experimental study of the flow characteristics and velocity fields in an operating room with laminar airflow ventilation. Journal of Building Engineering. 2020;29:101184. [Google Scholar]
  • 25.Bivolarova M, Ondráček J, Melikov A, Ždímal V. A comparison between tracer gas and aerosol particles distribution indoors: The impact of ventilation rate, interaction of airflows, and presence of objects. Indoor Air. 2017;27(6): 1201–1212. 10.1111/ina.12388 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Jianguo Wang

16 Mar 2021

PONE-D-21-06215

Comparing the effectiveness of negative pressure barrier devices in providing air clearance to prevent aerosol transmission

PLOS ONE

Dear Dr. Chen,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

  • It is an interesting research. 

  • I received comments and recommendation from one reviewe.

  • Please address these comments and really improve the quality in both English and technical issues.

Please submit your revised manuscript by Apr 30 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Jianguo Wang, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following in the Acknowledgments Section of your manuscript:

'..The study was funded by the Department of Health, Taipei City Government.'

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

a. Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

'The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.'

b. Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

3. We note that Figure 3 includes images of an individual.

As per the PLOS ONE policy (http://journals.plos.org/plosone/s/submission-guidelines#loc-human-subjects-research) on papers that include identifying, or potentially identifying, information, the individual(s) or parent(s)/guardian(s) must be informed of the terms of the PLOS open-access (CC-BY) license and provide specific permission for publication of these details under the terms of this license.

Please download the Consent Form for Publication in a PLOS Journal (http://journals.plos.org/plosone/s/file?id=8ce6/plos-consent-form-english.pdf). The signed consent form should not be submitted with the manuscript, but should be securely filed in the individual's case notes.

Please amend the methods section and ethics statement of the manuscript to explicitly state that the patient/participant has provided consent for publication: “The individual in this manuscript has given written informed consent (as outlined in PLOS consent form) to publish these case details”.

If you are unable to obtain consent from the subject of the photograph, you will need to remove the figure and any other textual identifying information or case descriptions for this individual.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This is an interesting article regarding the effectiveness of negative pressure barrier devices in providing air clearance to prevent aerosol transmission.

The topic is promising

I have the following comments:

- The whole manuscript should be edited for english-language usage

- In the introduction the authors must describe the main aim avoiding too detailed descriptions that should be reported in the methods (primary and secondary etc.)

- Is there a study period?

- In the introduction the authors give too many references to describe a concept (2-10). Should be reduced by adding the following guidelines on the use of laparoscopy in surgery (and the connection with aerosolization)

The risk of COVID-19 transmission by laparoscopic smoke may be lower than for laparotomy: a narrative review. Surg Endosc. 2020 Aug;34(8):3298-3305. doi: 10.1007/s00464-020-07652-y

Italian society of colorectal surgery recommendations for good clinical practice in colorectal surgery during the novel coronavirus pandemic. Tech Coloproctol. 2020 Jun;24(6):501-505. doi: 10.1007/s10151-020-02209-6

A Low-cost, Safe, and Effective Method for Smoke Evacuation in Laparoscopic Surgery for Suspected Coronavirus Patients. Ann Surg. 2020 Jul;272(1):e7-e8. doi: 10.1097/SLA.0000000000003965

- Were any patients involved? How many?

- The authors must clarify the methodology of the study

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Apr 21;16(4):e0250213. doi: 10.1371/journal.pone.0250213.r002

Author response to Decision Letter 0


25 Mar 2021

Comment from the reviewer:

Reviewer #1: This is an interesting article regarding the effectiveness of negative pressure barrier devices in providing air clearance to prevent aerosol transmission.

The topic is promising

Our response:

We are very pleased that you found our study interesting and informative. We have revised the manuscript thoroughly following your valuable suggestions. We hope the revised manuscript is now satisfactory.

Reviewer’s comment:

- The whole manuscript should be edited for English-language usage

Our response:

We apologize for the language in the manuscript. The document has now been proofread by an professional English language editor.

Reviewer’s comment:

- In the introduction the authors must describe the main aim avoiding too detailed descriptions that should be reported in the methods (primary and secondary etc.)

Our response:

Dear reviewer, we appreciate your valuable suggestion and adjusted the paragraph following your comment. We removed the part at the end of the introduction, which was more suitable in the study design and setting to improve the flow of the context.

The paragraph: ”Atomized glycerol was selected as a tracer gas and poly alpha olefins (PAO, diameter, 0.5–0.7 μm) was selected for aerosol concentration detection, based on previously published aerosol studies.24-26 The tracer gas with such a diameter was demonstrated to be best correlated with the aerosol droplet nuclei movement in an enclosed space.27 Our primary goal was to evaluate the effectiveness of each aerosol clearing device (AB, plastic aerosol bag, wall suction, and HEPA filter evacuator). Our secondary goal was to……” was removed from the introduction.

Reviewer’s comment:

- Is there a study period?

Our response:

Thank you for your query. This simulation experiment was conducted during 2020. The study period was April 20th to August 26th 2020.

Reviewer’s comment:

- In the introduction the authors give too many references to describe a concept (2-10). Should be reduced by adding the following guidelines on the use of laparoscopy in surgery (and the connection with aerosolization)

The risk of COVID-19 transmission by laparoscopic smoke may be lower than for laparotomy: a narrative review. Surg Endosc. 2020 Aug;34(8):3298-3305. doi: 10.1007/s00464-020-07652-y

Italian society of colorectal surgery recommendations for good clinical practice in colorectal surgery during the novel coronavirus pandemic. Tech Coloproctol. 2020 Jun;24(6):501-505. doi: 10.1007/s10151-020-02209-6

A Low-cost, Safe, and Effective Method for Smoke Evacuation in Laparoscopic Surgery for Suspected Coronavirus Patients. Ann Surg. 2020 Jul;272(1):e7-e8. doi: 10.1097/SLA.0000000000003965

Our response:

We appreciate your valuable comments and have revised our references for each concept in this regard. Furthermore, three important studies that link the procedures and aerosolization have been added to the Reference list.

Reviewer’s comment:

- Were any patients involved? How many?

Our response:

Since our practice acquired a negative-pressure barrier device on January 19th 2021, a total of 32 patients have received tracheal intubation using the negative-pressure device.

Reviewer’s comment:

- The authors must clarify the methodology of the study

Our response:

Dear reviewer, we appreciate your important suggestion and had clarify the experiment setting and methodology of the study in the study design and settings to make sure the readers can understand the flow field environment for aerosol visualization and the process for aerosol concentration detection.

Attachment

Submitted filename: Response to reviewers.docx

Decision Letter 1

Jianguo Wang

30 Mar 2021

PONE-D-21-06215R1

Comparing the effectiveness of negative-pressure barrier devices in providing air clearance to prevent aerosol transmission

PLOS ONE

Dear Dr. Chen,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

ACADEMIC EDITOR:

  • Minor revision may be still necessary.

  • You can decide which  references are suitable for citation to improve the quality of your manuscript.

==============================

Please submit your revised manuscript by May 14 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Jianguo Wang, PhD

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Congratulations to the authors for improving the manuscript.

I strongly suggest the following references regarding the use of the preventing systems for COVID-19 in surgery

The risk of COVID-19 transmission by laparoscopic smoke may be lower than for laparotomy: a narrative review. Surg Endosc. 2020 Aug;34(8):3298-3305. doi: 10.1007/s00464-020-07652-y

Italian society of colorectal surgery recommendations for good clinical practice in colorectal surgery during the novel coronavirus pandemic. Tech Coloproctol. 2020 Jun;24(6):501-505. doi: 10.1007/s10151-020-02209-6

A Low-cost, Safe, and Effective Method for Smoke Evacuation in Laparoscopic Surgery for Suspected Coronavirus Patients. Ann Surg. 2020 Jul;272(1):e7-e8. doi: 10.1097/SLA.0000000000003965

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Apr 21;16(4):e0250213. doi: 10.1371/journal.pone.0250213.r004

Author response to Decision Letter 1


30 Mar 2021

Comment from the reviewer:

Reviewer’s comment:

- In the introduction the authors give too many references to describe a concept (2-10). Should be reduced by adding the following guidelines on the use of laparoscopy in surgery (and the connection with aerosolization)

The risk of COVID-19 transmission by laparoscopic smoke may be lower than for laparotomy: a narrative review. Surg Endosc. 2020 Aug;34(8):3298-3305. doi: 10.1007/s00464-020-07652-y

A Low-cost, Safe, and Effective Method for Smoke Evacuation in Laparoscopic Surgery for Suspected Coronavirus Patients. Ann Surg. 2020 Jul;272(1):e7-e8. doi: 10.1097/SLA.0000000000003965

Our response:

We appreciate your valuable comments and have revised our references for each concept in this regard. Furthermore, these important studies that link the procedures and aerosolization have been added to the Reference list (10 and 20).

Attachment

Submitted filename: Response to reviewers.docx

Decision Letter 2

Jianguo Wang

5 Apr 2021

Comparing the effectiveness of negative-pressure barrier devices in providing air clearance to prevent aerosol transmission

PONE-D-21-06215R2

Dear Dr. Chen,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Jianguo Wang, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors have greatly improved the manuscript

I'm satisfied with the changes made

It can be considered for publication

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Acceptance letter

Jianguo Wang

7 Apr 2021

PONE-D-21-06215R2

Comparing the effectiveness of negative-pressure barrier devices in providing air clearance to prevent aerosol transmission

Dear Dr. Chen:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Jianguo Wang

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Video. The video demonstrates the aerosol movement to the foot and escape from the working channels of the aerosol box without suction systems.

    (MP4)

    Attachment

    Submitted filename: Response to reviewers.docx

    Attachment

    Submitted filename: Response to reviewers.docx

    Data Availability Statement

    All relevant data are within the paper and its Supporting Information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES